NuPathe Surges On Drug Safety Results (PATH)

Shares of specialty pharmaceutical company NuPathe

have climbed 16.28% to $7.00 on the back of promising top-line safety results for its migraine drug Zelrix. A total of 183 patients were enrolled in the trial, and Zelrix was well tolerated and the incidence of triptan-related adverse events was very low, with only three patients (1.6 percent) reporting a triptan adverse event with any Zelrix treatment over the course of the 12 month trial. "With strong results from this long term, open-label safety trial and the development of an in vitro analytical method for Zelrix, we continue to make steady progress toward the submission of a New Drug Application (NDA) prior to year end," said Jane Hollingsworth, chief executive officer of NuPathe. "Based upon the growing body of clinical evidence, we believe Zelrix, if approved, should provide an efficacious and well-tolerated treatment option for many of the millions of underserved migraine patients in the U.S. in a novel transdermal formulation." NuPathe Inc. (NuPathe) is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company's product candidate, Zelrix, is a single-use patch applied to the arm or thigh for the treatment of migraine.